Cardiopulmonary dysfunctions caused by ADP-induced platelet aggregation.

Platelet activation and aggregation during cardiopulmonary bypass.

Cardiopulmonary dysfunctions caused by intravenous collagen-induced release of ADP and ATP from platelets.

In vitro platelet aggregation and oxidative stress caused by amorphous silica nanoparticles.

Letter: Is platelet aggregation by isoantibodies always real aggregation?

Xanthines inhibit human platelet aggregation induced by platelet-activating factor.

Reversal of platelet aggregation by prostacyclin.

Inhibition of platelet aggregation by "guggulu" steroids.

Platelet aggregation induced by swine influenza vaccine.

Platelet aggregation by strains of enterococci.

Inhibition of platelet aggregation by some flavonoids.

Human platelet aggregation by Yersinia pseudotuberculosis is mediated by invasin.

Shear-induced platelet aggregation.

Platelet protection by aprotinin in cardiopulmonary bypass: electron microscopic study.

Platelet aggregation induced by platelet-activating factor is suppressed by cystine protease inhibitor.

[Significance of photometric demonstration of variations in platelet form during aggregation caused by ADP: reality or artefact].

In vitro effect of plasmin on human platelet function in plasma. Inhibition of aggregation caused by fibrinogenolysis.

Platelet aggregation and chlorpromazine therapy.

Platelet aggregation in diabetic retinopathy.

Platelet aggregation in diabetes mellitus.

Platelet aggregation in Raynaud's phenomenon.

Inhibition of human platelet aggregation by monovalent antifibrinogen antibody fragments.

Platelet aggregation by hepatitis B surface antigen-antibody complexes.

Novel inhibitors of platelet aggregation.

Platelet aggregation and serum prolactin.

Suggest Documents

Platelet activation and aggregation during cardiopulmonary bypass.

Cardiopulmonary dysfunctions caused by intravenous collagen-induced release of ADP and ATP from platelets.

In vitro platelet aggregation and oxidative stress caused by amorphous silica nanoparticles.

Letter: Is platelet aggregation by isoantibodies always real aggregation?

Xanthines inhibit human platelet aggregation induced by platelet-activating factor.

Reversal of platelet aggregation by prostacyclin.

Inhibition of platelet aggregation by "guggulu" steroids.

Platelet aggregation induced by swine influenza vaccine.

Platelet aggregation by strains of enterococci.

Inhibition of platelet aggregation by some flavonoids.

Human platelet aggregation by Yersinia pseudotuberculosis is mediated by invasin.

Shear-induced platelet aggregation.

Platelet protection by aprotinin in cardiopulmonary bypass: electron microscopic study.

Platelet aggregation induced by platelet-activating factor is suppressed by cystine protease inhibitor.

[Significance of photometric demonstration of variations in platelet form during aggregation caused by ADP: reality or artefact].

In vitro effect of plasmin on human platelet function in plasma. Inhibition of aggregation caused by fibrinogenolysis.

Platelet aggregation and chlorpromazine therapy.

Platelet aggregation in diabetic retinopathy.

Platelet aggregation in diabetes mellitus.

Platelet aggregation in Raynaud's phenomenon.

Inhibition of human platelet aggregation by monovalent antifibrinogen antibody fragments.

Platelet aggregation by hepatitis B surface antigen-antibody complexes.

Novel inhibitors of platelet aggregation.

Platelet aggregation and serum prolactin.

Cardiopulmonary dysfunctions caused by ADP-induced platelet aggregation.

Recommend Documents

Follow Us